Cantab Anti-infectives Ltd is focused exclusively on the discovery and development of novel antibacterial agents to treat bacterial infections. The product pipeline has been derived by optimising the therapeutic properties of peptide-derived antibiotics, namely lantibiotics and polymyxins. This has been achieved through a combination of molecular engineering at the genetic level together with medicinal chemistry to fully explore the structure-activity relationships of these agents.

Cantab Anti-Infectives continues to explore new product opportunities both within its existing candidate series and from new agents with the potential to offer significant advantage over current therapies.